Fusion Antibodies (LON:FAB) Stock Price Down 11.3% – Here’s Why

Fusion Antibodies plc (LON:FAB)’s share price dropped 11.3% during trading on Thursday . The stock traded as low as GBX 4.33 ($0.06) and last traded at GBX 4.35 ($0.06). Approximately 954,842 shares changed hands during trading, a decline of 14% from the average daily volume of 1,116,575 shares. The stock had previously closed at GBX 4.90 ($0.06).

Fusion Antibodies Price Performance

The firm has a market cap of £4.14 million, a price-to-earnings ratio of -120.00 and a beta of 0.49. The company has a current ratio of 3.87, a quick ratio of 2.36 and a debt-to-equity ratio of 2.40. The company has a 50 day moving average of GBX 3.61 and a 200 day moving average of GBX 3.51.

Insider Buying and Selling

In other news, insider Adrian Kinkaid bought 83,728 shares of the stock in a transaction on Wednesday, October 16th. The stock was purchased at an average price of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,373.36). In other news, insider Adrian Kinkaid bought 83,728 shares of the stock in a transaction on Wednesday, October 16th. The stock was purchased at an average price of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,373.36). Also, insider Richard John Buick bought 94,825 shares of the stock in a transaction on Monday, September 9th. The shares were purchased at an average price of GBX 3 ($0.04) per share, with a total value of £2,844.75 ($3,714.74). In the last quarter, insiders have acquired 448,553 shares of company stock valued at $1,429,387. 11.39% of the stock is owned by company insiders.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.